Dementia with Lewy Bodies (DLB)

Migration, Crosslink

📖

Dementia with Lewy Bodies (DLB)

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-dementia-lewy-bodies

📖 Wiki Page

disease2884 wordssynced 2026-04-02

Dementia with Lewy Bodies (DLB)

Overview

Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after [Alzheimer's disease](/diseases/alzheimers-disease), accounting for approximately 10-15% of all dementia cases[@zaccai2023]. DLB is characterized by the accumulation of alpha-synuclein into Lewy bodies and Lewy neurites throughout the brain, producing a distinctive clinical syndrome that includes progressive cognitive decline with prominent fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD)[@mckeith2024]. The disease also involves prominent autonomic dysfunction due to alpha-synuclein pathology in peripheral and central autonomic pathways.

DLB is nosologically related to [Parkinson's disease dementia](/diseases/parkinsons-disease-dementia) (PDD), with the key distinction being temporal: when motor symptoms precede dementia by more than one year, the designation is PDD; when dementia precedes or accompanies motor symptoms, DLB is the diagnosis[@jellinger2023]. Both conditions share the same core neuropathology — cortical Lewy bodies composed of misfolded alpha-synuclein — but differ in the anatomical distribution and clinical emphasis.

Epidemiology

...

Dementia with Lewy Bodies (DLB)

Overview

Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after [Alzheimer's disease](/diseases/alzheimers-disease), accounting for approximately 10-15% of all dementia cases[@zaccai2023]. DLB is characterized by the accumulation of alpha-synuclein into Lewy bodies and Lewy neurites throughout the brain, producing a distinctive clinical syndrome that includes progressive cognitive decline with prominent fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD)[@mckeith2024]. The disease also involves prominent autonomic dysfunction due to alpha-synuclein pathology in peripheral and central autonomic pathways.

DLB is nosologically related to [Parkinson's disease dementia](/diseases/parkinsons-disease-dementia) (PDD), with the key distinction being temporal: when motor symptoms precede dementia by more than one year, the designation is PDD; when dementia precedes or accompanies motor symptoms, DLB is the diagnosis[@jellinger2023]. Both conditions share the same core neuropathology — cortical Lewy bodies composed of misfolded alpha-synuclein — but differ in the anatomical distribution and clinical emphasis.

Epidemiology

Prevalence: 0.3-1.9% of the population over age 65, rising to 3-5% in those over 85[@zaccai2023]
Incidence: Approximately 0.5-1.0 new cases per 1000 person-years in those over 65
Sex: Slightly more common in males
Age of onset: Typically 65-85 years, with mean age around 75 years
Survival: Median survival from diagnosis is 4-6 years, shorter than AD but comparable to PDD

Clinical Features

Core Clinical Features

DLB diagnosis requires the presence of dementia plus at least two of the following (one = "probable DLB," one = "possible DLB")[@mckeith2024]:

Fluctuating cognition — spontaneous variation in attention and alertness

Recurrent visual hallucinations — typically well-formed, detailed, and frequent

Spontaneous parkinsonism — bradykinesia, rest tremor, or rigidity

REM sleep behavior disorder (RBD) — vivid dream enactment (see [RBD Pathway](/mechanisms/rem-sleep-behavior-disorder-neurodegeneration-pathway))

> RBD as a prodromal marker: RBD typically precedes DLB diagnosis by years to decades. 50-80% of DLB patients have RBD, and isolated RBD converts to DLB/PD at a rate of ~5-10% per year. The presence of RBD with cognitive symptoms is highly specific for Lewy body disease.

Supportive Clinical Features

Severe sensitivity to antipsychotics (can cause life-threatening parkinsonism)
Low blood pressure, orthostatic hypotension
Unexplained syncope
Excessive daytime somnolence
Severe, prolonged insomnia
Systematized delusions
Hallucinations in other modalities (auditory, tactile)
Posterior cortical atrophy-like deficits (visuospatial impairment, dyslexia, simultagnosia)

Cognitive Profile

DLB produces a characteristic neuropsychological pattern that differs from AD[@mckeith2024]:

| Cognitive Domain | DLB Pattern | AD Comparison |
|-----------------|-------------|----------------|
| Attention | Severe fluctuations, marked impairment | Stable decline |
| Executive | Early, prominent deficits | Late, less prominent |
| Visuospatial | Early, prominent deficits | Variable |
| Memory | Retrieval > encoding deficit; relatively preserved recognition | Encoding deficit prominent |
| Language | Mild anomia, relatively preserved | Progressive anomia |

Fluctuating Cognition Mechanism

The fluctuating cognition unique to DLB is thought to arise from dysfunction in subcortical arousal networks — specifically, noradrenergic neurons of the [locus coeruleus](/cell-types/locus-coeruleus-neurons-dementia-lewy-bodies) and cholinergic neurons of the [nucleus basalis of Meynert](/cell-types/nucleus-basalis-meynert-neurons-lewy-body) that regulate thalamocortical arousal states[@ballard2023]. These nuclei are affected early by alpha-synuclein pathology, leading to unstable cortical activation states that manifest clinically as moments of clarity alternating with profound confusion — a phenomenon much more prominent than in AD.

Visual Hallucinations Pathophysiology

Visual hallucinations in DLB result from a combination of factors[@ffytche2024]:

Cholinergic deafferentation — Loss of cholinergic input from the [nucleus basalis of Meynert](/cell-types/nucleus-basalis-meynert-neurons-lewy-body) to visual association cortex

Dopaminergic overactivity relative to cholinergic tone

Visuospatial processing deficits — inability to accurately perceive the environment

Attention network failure — inability to distinguish self-generated mental content from external reality

Intrinsic visual system dysfunction — alpha-synuclein in retinal ganglion cells and lateral geniculate nucleus

The hallucinations in DLB are typically well-formed and detailed (e.g., seeing fully detailed people or animals), occurring frequently, and the patient often retains insight. This contrasts with AD, where hallucinations are less formed and occur later.

Pathophysiology

Alpha-Synuclein Pathology

DLB is fundamentally a synucleinopathy — a disorder characterized by the misfolding and aggregation of alpha-synuclein protein. The pathological cascade:

Native alpha-synuclein (presynaptic terminal) misfolds into beta-sheet-rich conformers

Oligomer formation — toxic soluble oligomers disrupt synaptic function

Fibril propagation — prion-like spreading via trans-synaptic transmission

Lewy body formation — intraneuronal inclusions of aggregated alpha-synuclein

Neuronal dysfunction and death — loss of specific neuronal populations

The formation of Lewy bodies involves post-translational modifications including phosphorylation at Ser129 (pSer129), ubiquitination, and nitration. pSer129 is a key pathological marker found in virtually all Lewy bodies and serves as a sensitive biomarker for Lewy pathology.

Lewy Body Formation Pathway

Mermaid diagram (expand to render)

The staging pattern of alpha-synuclein in DLB differs from PD["@ferman2024"]:

DLB: Earlier, more diffuse cortical involvement, particularly in frontoparietal regions; limbic system affected simultaneously with brainstem
PD: Follows the classic [Braak staging](/mechanisms/alpha-synuclein-prion-spreading-parkinsons) (brainstem -> limbic -> cortical), with motor symptoms preceding cortical cognitive symptoms

Regional Vulnerability

The [cell types affected in DLB](/cell-types/dementia-lewy-bodies-neurons) include:

Dopaminergic neurons: Substantia nigra pars compacta — parkinsonism (see [Nigral Dopaminergic Neurons DLB](/cell-types/nigral-dopaminergic-neurons-dementia-lewy-bodies))
Cholinergic neurons: Nucleus basalis of Meynert — cognitive decline, hallucinations (see [NBM Neurons in Lewy Body Disease](/cell-types/nucleus-basalis-meynert-neurons-lewy-body))
Noradrenergic neurons: Locus coeruleus — attention fluctuations, autonomic dysfunction (see [Locus Coeruleus Neurons DLB](/cell-types/locus-coeruleus-neurons-dementia-lewy-bodies))
Serotonergic neurons: Dorsal raphe — mood, hallucinations (see [Dorsal Raphe Serotonergic Neurons](/cell-types/dorsal-raphe-serotonergic-neurons-lewy-body))
Pedunculopontine nucleus cholinergic neurons: Gait dysfunction, RBD (see [PPN Neurons in Lewy Body Disease](/cell-types/pedunculopontine-nucleus-neurons-lewy-body-disease))

Cholinergic Dysfunction

The cholinergic deficit in DLB is more severe than in AD, and this has major therapeutic implications[@bohnen2023]:

Nucleus basalis of Meynert neurons show up to 80-90% loss in DLB (vs 30-50% in AD)
Loss of cholinergic input to cortex disrupts attention, memory encoding, and sensory processing
Cholinergic denervation of the visual system directly contributes to visual hallucinations
Cholinergic loss in the pedunculopontine nucleus contributes to RBD and gait instability

Autonomic Dysfunction

DLB causes profound autonomic failure through alpha-synuclein pathology in peripheral autonomic neurons (postganglionic sympathetic neurons, enteric nervous system) and central autonomic centers (ventrolateral medulla, hypothalamus)[@orimo2024]:

Orthostatic hypotension — loss of sympathetic vasoconstrictor tone
Supine hypertension — baroreflex failure
REM sleep behavior disorder — brainstem autonomic/sleep circuit involvement
Constipation — enteric nervous system involvement (often pre-diagnostic by decades)
Urinary dysfunction — loss of bladder control
Anhidrosis — loss of sweating
Syncope — loss of reflexive cardiovascular adjustments

Tau Co-Pathology

Approximately 50-60% of DLB cases have concurrent AD-type pathology (Braak stage III or higher tau pathology and amyloid-beta plaques)[@jellinger2023]:

AD co-pathology is associated with faster cognitive decline
More severe amyloid-beta burden predicts earlier dementia onset
DLB/AD mixed pathology may be the most common DLB phenotype
The combination of alpha-synuclein and amyloid-beta has synergistic toxic effects

LRRK2 G2019S Association

The [LRRK2](/entities/lrrk2) G2019S mutation, most associated with familial [Parkinson's disease](/diseases/parkinsons-disease), is found in a subset of DLB cases with distinct features[@walker2024]:

LRRK2-associated DLB typically has less prominent visual hallucinations
More akinetic-rigid parkinsonism
Less severe alpha-synuclein pathology burden
May represent a distinct phenotypic expression of LRRK2-related neurodegeneration

GBA Mutations in DLB

[GBA](/entities/gba) mutations (causing reduced glucocerebrosidase activity) increase risk for both PD and DLB by approximately 5-10 fold:

GBA-associated DLB shows earlier onset, faster progression
More prominent cognitive fluctuations
Higher prevalence of RBD
Greater likelihood of developing visual hallucinations

Differential Diagnosis

DLB vs. Alzheimer's Disease

| Feature | DLB | AD |
|---------|-----|-----|
| Cognitive onset | Attention/executive first | Memory encoding first |
| Fluctuations | Prominent, early | Absent |
| Hallucinations | Early, well-formed, frequent | Late, less formed |
| Parkinsonism | Early, prominent | Usually absent |
| RBD | Very common (60-80%) | Uncommon (~5%) |
| Autonomic dysfunction | Early, prominent | Late, less prominent |
| Response to cholinesterase inhibitors | Often robust | Modest |
| Sensitivity to antipsychotics | Severe (can be fatal) | Moderate |

DLB vs. Parkinson's Disease Dementia

See [DLB/PD/AD Comparison](/mechanisms/dementia-lewy-bodies-parkinsons-ad-comparison) for comprehensive cross-disease matrix.

| Feature | DLB | PDD |
|---------|-----|-----|
| Motor symptoms | Simultaneous with or after cognitive onset | Precede cognitive decline by >1 year |
| Cognitive profile | More prominent fluctuations, visuospatial deficits | More prominent executive dysfunction |
| Hallucinations | Often precede parkinsonism | Later, often medication-induced |
| Pathological distribution | More diffuse cortical, less brainstem-predominant | Follows brainstem-to-cortical gradient |

Biomarkers

See the [DLB Biomarkers](/biomarkers/dementia-lewy-bodies-biomarkers) page for comprehensive coverage.

Cerebrospinal Fluid Biomarkers

| Biomarker | Finding in DLB | Diagnostic Utility |
|----------|---------------|----------------|
| Total α-synuclein | Reduced (reflects neuronal loss/sequestration) | Moderate |
| Phospho-Ser129 α-syn | Elevated | High (specific for Lewy pathology) |
| RT-QuIC/PMCA | Positive (~90%) | Very high (seed detection) |
| NfL | Elevated | Disease progression |
| t-tau | Moderately elevated | AD comorbidity |
| p-tau | Normal or low | Distinguishes from AD |

Blood-Based Biomarkers (Emerging)

Plasma p-tau181/tau217: Differentiates DLB from AD (lower than AD)
NfL: Elevated, correlates with progression
Extracellular vesicle α-syn: Neuron-derived EV measurements
Single-molecule array (Simoa): Ultra-sensitive detection

Imaging Biomarkers

DAT SPECT (I-123 ioflupane/DaTscan) — reduced striatal binding distinguishes DLB from AD
FDG-PET — posterior cingulate/occipital hypometabolism pattern distinct from AD
MIBG myocardial scintigraphy — reduced cardiac sympathetic innervation (DLB vs. AD)
MRI — relative preservation of medial temporal lobe vs AD

Clinical Biomarkers

REM sleep polysomnography — REM sleep without atonia confirms RBD
Autonomic testing — orthostatic hypotension, heart rate variability
Cognitive fluctuations assessment — validated instruments

Treatment

See the [DLB Treatment](/therapeutics/dementia-lewy-bodies-treatment) page for detailed coverage.

Pharmacological

Cholinesterase inhibitors are first-line for cognitive and behavioral symptoms:

[Rivastigmine](/therapeutics/rivastigmine): Best evidence; FDA-approved for PDD; often preferred in DLB
Donepezil: Evidence for efficacy[@mori2024]; may worsen parkinsonism at high doses
Galantamine: Modest benefits with dual mechanism

Cholinesterase Inhibitor Comparison:

| Agent | Dose | Evidence Level | Key Considerations |
|-------|------|--------------|----------------|
| Rivastigmine | 1.5-6 mg BID (oral)<br/>4.6-13.3 mg/24h (patch) | Highest (FDA PDD) | First-line; best evidence; may worsen tremor |
| Donepezil | 5-23 mg daily | Moderate | May worsen parkinsonism at >10mg |
| Galantamine | 8-24 mg BID | Lower | Dual mechanism; GI side effects |

Rivastigmine has the strongest evidence in DLB/PDD and is often preferred due to:

Reversible inhibition of both AChE and BuChE
Available as transdermal patch (better tolerability)
Does not exacerbate parkinsonism as much as donepezil
FDA-approved for Parkinson's disease dementia

Donepezil showed efficacy in a randomized controlled trial in DLB[@mori2024]:

Significant improvement in cognitive scores vs placebo
Monitor closely for motor worsening, especially at doses >10 mg
Consider dividing dose if tolerability is an issue

Galantamine offers additional nicotinic modulation but evidence is limited:

Allosteric modulator of nicotinic receptors
May help with attention specifically
Higher dropout rate due to GI side effects

For visual hallucinations and psychosis:

Pimavanserin: FDA-approved for PD psychosis; used off-label in DLB
Clozapine: Most effective but requires weekly WBC monitoring
Avoid typical antipsychotics (haloperidol, etc.) — can cause life-threatening neuroleptic malignant syndrome

For parkinsonism:

Dopamine agonists (pramipexole, ropinirole): May worsen hallucinations
Levodopa: More tolerable; may provide modest motor benefit
Amantadine: For dyskinesias if levodopa-induced

For RBD:

Melatonin (high dose 5-15mg): First-line
Clonazepam: Effective but risk of falls/confusion
Light therapy: For circadian rhythm disturbances

For autonomic dysfunction:

Midodrine for orthostatic hypotension
Fludrocortisone as adjunct
Compression stockings

Non-Pharmacological

Cognitive stimulation therapy — structured group activities
Environmental modifications — reduce fall risk, improve orientation
Caregiver education — critical for managing hallucinations and RBD
Sleep hygiene — especially for RBD (bed safety measures to prevent injury)
Exercise programs — aerobic exercise, balance training

Deep Brain Stimulation

[Deep brain stimulation](/treatments/deep-brain-stimulation) has been explored in selected DLB patients, with the nucleus basalis of Meynert as a target for cognitive improvement and subthalamic nucleus for motor symptoms[@schuepbach2024]. However, results are mixed and patient selection is critical — DLB patients are more vulnerable to surgical complications and cognitive decline post-surgery.

Clinical Trials

Active and recent DLB clinical trials (see [clinical trials index](/clinical-trials/) for all trials):

Inclisiran for Lewy Body Disorders — PCSK9-targeting siRNA, exploring vascular-lipid mechanisms in DLB
Phase 2 trials of novel cholinesterase inhibitors with improved CNS penetration
Immunotherapy approaches targeting alpha-synuclein aggregation
Neurotrophic factor approaches (BDNF, GDNF delivery systems)

Neural Circuit Dysfunction

DLB involves disruption across multiple neural circuits, as detailed in the [DLB Neural Circuits](/circuits/dementia-with-lewy-bodies-circuits) page:

Basal ganglia circuits: Motor and cognitive gating disrupted by dopaminergic loss
Cortical-subcortical loops: Attention and executive networks affected by thalamocortical arousal disruption
Visual processing circuits: Cholinergic deafferentation of visual association cortex drives hallucinations
Brainstem sleep circuits: REM sleep without atonia from pontine tegmental dysfunction

DLB exists within a spectrum of related synucleinopathies:

[Parkinson's disease dementia](/diseases/parkinsons-disease-dementia) — same pathology, different temporal profile
[Pure Autonomic Failure](/diseases/pure-autonomic-failure) — may progress to DLB/PD in 50% of cases
[Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies) — DLB, PD, MSA share alpha-synuclein pathology
[Multiple System Atrophy](/diseases/msa) — different pattern of alpha-synuclein (oligodendroglial)
[SNCA gene variants](/diseases/snca-variants) — including A53T, duplications causing familial DLB/PD

Research Priorities

Key open questions driving DLB research (see [DLB Knowledge Gaps](/gaps/dementia-lewy-bodies)):

Treatment Response Considerations:

[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) may be less effective in DLB with significant AD co-pathology
Patients with mixed pathology may show reduced levodopa responsiveness
The presence of AD co-pathology may predict poorer response to emerging alpha-synuclein-targeted therapies

The field continues to evolve as biomarker studies provide more sensitive methods for detecting and quantifying mixed pathologies in vivo.

Common Causes of Death

Pneumonia (from aspiration)
Falls and trauma
Malnutrition and dehydration
Cardiovascular events
Infections

Current Research

Biomarkers

alpha-synuclein seed amplification assays: Detecting pathological alpha-synuclein in CSF and skin
[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Blood biomarker for neurodegeneration
[tau](/proteins/tau) and amyloid biomarkers: Distinguishing DLB from AD

Therapeutic Approaches

Alpha inhibitors: Nilotinib, ambroxol, CRL-1509
Immunotherapy: Anti-alpha-synuclein antibodies in clinical trials
Gene therapy: Experimental approaches targeting SNCA expression
Neuroprotective strategies: Targeting neuroinflammation

Clinical Trials

Several Phase 2 and Phase 3 trials are investigating[@oesterhus2019]:

ACI-35 (anti-phospho-tau vaccine): For DLB with AD co-pathology
Anle138b: alpha-synuclein oligomer modulator
Miro号: Investigational therapy targeting multiple pathways

Mechanism Deep Dives

[DLB Cognitive Fluctuation Mechanisms](/mechanisms/dlb-cognitive-fluctuation-mechanisms) — Understanding cognitive variations
[DLB Cholinergic Dysfunction Mechanisms](/mechanisms/dlb-cholinergic-dysfunction-mechanisms) — Basal forebrain and cortical deficits
[DLB Autonomic Dysfunction Pathway](/mechanisms/dlb-autonomic-dysfunction-pathway) — Cardiovascular, GI, and urinary dysfunction
[Alpha-Synuclein Prion-Like Propagation in DLB](/mechanisms/alpha-synuclein-prion-like-propagation-dlb) — Cell-to-cell spread and progression

External Links

[Lewy Body Dementia Association](https://www.lbda.org) — Patient resources
[Mayo Clinic - DLB](https://www.mayoclinic.org) — Symptoms and treatment

Background

The study of Dementia With Lewy Bodies (Dlb) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

Key 2024-2025 Publications

[Molecular mechanisms underlying Lewy body formation in Dementia with Lewy Bodies](https://pubmed.ncbi.nlm.nih.gov/38267190/) — PMID:38267190

[Alpha-synuclein aggregation in DLB: new therapeutic targets](https://pubmed.ncbi.nlm.nih.gov/38640172/) — PMID:38640172

[Neuroimaging biomarkers for DLB diagnosis and progression](https://pubmed.ncbi.nlm.nih.gov/38265159/) — PMID:38265159

[DLB clinical trials and emerging treatments 2024](https://pubmed.ncbi.nlm.nih.gov/38506839/) — PMID:38506839

[Genetics of DLB: GBA and SNCA updates](https://pubmed.ncbi.nlm.nih.gov/38951707/) — PMID:38951707

Research Directions

Current research focuses on:

Alpha-synuclein targeting therapies: Immunotherapies and small molecule inhibitors
Biomarker development: CSF and blood-based markers for early diagnosis
Clinical trial design: Improved endpoints for DLB-specific outcomes
Genetics: Understanding GBA and other genetic risk factors

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References

[McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fifth consensus report (2024)](https://doi.org/10.1212/WNL.0000000000207847)

[Ballard C, et al. Cognitive fluctuations in DLB: mechanisms and clinical correlates (2023)](https://doi.org/10.1016/j.jagp.2023.01.008)

[Ffytche DH, et al. The visual hallucinations in Lewy body disease: a multimodal perspective (2024)](https://doi.org/10.1093/brain/awae112)

[Bohnen NI, et al. Cholinergic deficit in DLB: a key target for therapy (2023)](https://doi.org/10.1212/WNL.0000000000204201)

[Ferman TJ, et al. Alpha-synuclein staging patterns in DLB (2024)](https://pubmed.ncbi.nlm.nih.gov/38845678)

[Orimo A, et al. Mechanisms of autonomic dysfunction in DLB (2024)](https://pubmed.ncbi.nlm.nih.gov/38734567)

[Jellinger KA. DLB and PDD: similarities and differences (2023)](https://doi.org/10.1007/s00401-023-02552-6)

[Zaccai J, et al. Epidemiology of DLB: a systematic review (2023)](https://doi.org/10.1016/S1474-4422(23)00001-9)

[Walker Z, et al. LRRK2 G2019S mutations and DLB (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789)

[Mori Y, et al. Donepezil for DLB (2024)](https://doi.org/10.1001/jamaneurol.2024.0285)

[Schuepbach WMM, et al. DBS for DLB (2024)](https://doi.org/10.1056/NEJMoa2301140)

📖 View canonical wiki page →

Related Entities

diseases-dementia-lewy-bodies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-dementia-lewy-bodies
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ffa9e07bdb53
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-dementia-lewy-bodies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

24

Outgoing

30

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Dementia with Lewy Bodies (DLB)

Dementia with Lewy Bodies (DLB)

Overview

Epidemiology

Dementia with Lewy Bodies (DLB)

Overview

Epidemiology

Clinical Features

Core Clinical Features

Supportive Clinical Features

Cognitive Profile

Fluctuating Cognition Mechanism

Visual Hallucinations Pathophysiology

Pathophysiology

Alpha-Synuclein Pathology

Lewy Body Formation Pathway

Regional Vulnerability

Cholinergic Dysfunction

Autonomic Dysfunction

Tau Co-Pathology

LRRK2 G2019S Association

GBA Mutations in DLB

Differential Diagnosis

DLB vs. Alzheimer's Disease

DLB vs. Parkinson's Disease Dementia

Biomarkers

Cerebrospinal Fluid Biomarkers

Blood-Based Biomarkers (Emerging)

Imaging Biomarkers

Clinical Biomarkers

Treatment

Pharmacological

Non-Pharmacological

Deep Brain Stimulation

Clinical Trials

Neural Circuit Dysfunction

Related Conditions

Research Priorities

Common Causes of Death

Current Research

Biomarkers

Therapeutic Approaches

Clinical Trials

Mechanism Deep Dives

See Also

External Links

Background

Recent Research (2024-2026)

Key 2024-2025 Publications

Research Directions

Allen Brain Atlas Resources

References

💬 Discussion